December 14, 2025/
This is the 19th volume, 11th issue of the EPVC’s monthly newsletter, published in November 2025. It serves as an official communication from the Egyptian Drug Authority (EDA) to healthcare professionals,...
ALVigiLance is a dedicated pharmacovigilance platform designed to support the healthcare team in ensuring safer medication use. Our mission is simple yet vital: to provide trusted insights, practical tools, and up-to-date resources that empower healthcare professionals to identify, prevent, and manage adverse drug reactions (ADRs).
Simplified, practical guides on drug safety and monitoring.
Real-world examples to strengthen your clinical decision-making.
Summaries of global drug warnings and regulatory actions.
Strategies for adverse event reporting, risk management, and patient counseling.
To create a proactive community of healthcare providers who champion medication safety and improve patient outcomes through shared knowledge and vigilance.
Medication safety is everyone’s responsibility. Explore, learn, and engage with ALVigiLance — because together, we can reduce risks and save lives.
This is the 19th volume, 11th issue of the EPVC’s monthly newsletter, published in November 2025. It serves as an official communication from the Egyptian Drug Authority (EDA) to healthcare professionals,...
The UK Centre of Excellence for Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx) has developed a landmark guideline on CYP2C19 genotype testing for clopidogrel, published in...
This document is a supplementary publication from the European Medicines Agency (EMA). It provides the exact legal wording that must be inserted into the official product information for medicines,...
